What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?
Would you still treat with neoadjuvant KEYNOTE-522?
Community PollStarted
Would you treat a cT2N0 grade 2-3, ER-, PR variably positive, HER2- breast cancer with neoadjuvant chemo+pembro (KN522)?
54 physicians have voted
Join Mednetto vote and see how they answered.
3 Answers
Mednet MemberInvited Expert
Medical Oncology · Ohio State University
Answered on
Since weakly hormone-positive, HER2-negative breast cancer behaves more similarly to triple-negative breast cancer than strongly hormone receptor-positive breast cancer (Poterala et al., PMID 35676188), I would approach this patient similarly to patients with stage 2 triple-negative breast cancer. I...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Answered on
Yes, I would treat as TNBC with KN522 and if not a pCR, give adjuvant olaparib with pembro.
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Lehigh Valley Physicians Group
Answered on
I agree - would treat at TNBC with KN-522
Join for free or sign in to see the full answer